Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
34Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05209256CT.gov Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC | — | Unknown | — | — | — |
NCT03452592CT.gov Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M | — | Terminated | — | — | — |
NCT03127449CT.gov AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | — | Terminated | — | — | — |
NCT02973763CT.gov Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alflutinib (this asset) | The First Affiliated Hospital of Henan University of Science and Technology | P2/3 | CC · 42 |
| Nivolumab | Fred Hutchinson Cancer Center | P4 | A |
| Vinorelbine Ditartrate | Intergroupe Francophone de Cancerologie Thoracique | P4 | A |
| Lazertinib | Janssen Research & Development, LLC | P3 | A |
| Nogitecan | Fox Chase Cancer Center | P3 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Ipilimumab | University of Chicago | P3 | BBB |
| Benmelstobart | The Third Xiangya Hospital of Central South University | P3 | BBB |
| Nintedanib | Second Hospital of Shanxi Medical University | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alflutinib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 15, 2026. Accessed July 16, 2026. https://terminal.floatz.ai/assets/alflutinib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →